LTRN - Lantern Pharma Inc Stock Price, Fair Value and News

$3.52+0.05 (+1.44%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LTRN Price Action

Last 7 days

-7.4%

Last 30 days

-7.8%

Last 90 days

-16.2%

Trailing 12 Months

10.3%

LTRN RSI Chart

LTRN Valuation

Market Cap

39.4M

Price/Earnings (Trailing)

-2.08

Price/Sales (Trailing)

70.71

Price/Free Cashflow

-2.33

LTRN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LTRN Fundamentals

LTRN Revenue

Revenue (TTM)

556.8K

Rev. Growth (Yr)

-47.26%

Rev. Growth (Qtr)

-12.05%

LTRN Earnings

Earnings (TTM)

-18.9M

Earnings Growth (Yr)

7.29%

Earnings Growth (Qtr)

3.55%

LTRN Profitability

Return on Equity

-197.36%

Return on Assets

-138.85%

Free Cashflow Yield

-42.83%

LTRN Investor Care

Shares Dilution (1Y)

3.71%

Diluted EPS (TTM)

-1.75

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	730.8K	644.5K	556.8K	0
2024	756.7K	748.1K	739.4K	0
2023	315.7K	378.5K	0	765.4K
2022	102.0K	136.1K	170.2K	204.4K
2021	0	0	0	67.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

CEO	Mr. Panna Sharma PH.D.
WEBSITE	lanternpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	22

Lantern Pharma Inc Frequently Asked Questions

What is the ticker symbol for Lantern Pharma Inc? What does LTRN stand for in stocks?

LTRN is the stock ticker symbol of Lantern Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lantern Pharma Inc (LTRN)?

As of Wed Dec 03 2025, market cap of Lantern Pharma Inc is 39.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LTRN stock?

You can check LTRN's fair value in chart for subscribers.

Is Lantern Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether LTRN is over valued or under valued. Whether Lantern Pharma Inc is cheap or expensive depends on the assumptions which impact Lantern Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LTRN.

What is Lantern Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, LTRN's PE ratio (Price to Earnings) is -2.08 and Price to Sales (PS) ratio is 70.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LTRN PE ratio will change depending on the future growth rate expectations of investors.